• Home
  • Search Results

Search Results

Open
Cancer - Lymphoma
27 studies match your search
Open

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Have you been recently diagnosed with Diffuse Large B Cell Lymphoma? Are you over 75 years of age? If so, you may be able to take part in a research study looking at the safety of giving a new study drug CC-486 (oral azacitidine) in addition to the standard chemotherapy drug combination used to treat this disease.

Age & Gender
  • 75 years ~ 99 years
  • Male, Female
Study Interest
  • Aging
  • Cancer (Lymphoma)
Open

CAR-T cells targeting the kappa antigen for Relapsed/ Refractory mantle cell and indolent non-Hodgkin lymphomas

Do you have mantle cell lymphoma or other non-Hodgkin lymphoma that has either come back or did not get better with your last treatment? If so, you may be able to take part in a study that will modify your own immune cells to see if it may treat your cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Lymphoma)
Open

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Have you been diagnosed with primary central nervous system (CNS) lymphoma? If so you may be able to take part in a research study looking at whether using the study drugs lenalidomide, and nivolumab can be safely used in addition to the standard treatment of primary CNS lymphoma, and which dose is the most adequate when they are used together.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

Phase II Study of CD30 CAR for relapsed/refractory CD30+ T Cell Lymphoma

Do you have Peripheral T Cell Lymphoma? Has your cancer come back or did it not get better with the last treatment you were given? If so, you may be eligible to participate in this gene therapy research study to learn more about using your own modified immune cells as possible treatment.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

CD19 CAR T-cells containing a Safety Switch to Treat Relapsed/Refractory B-cell Lymphoma

Have you been diagnosed with B-Cell Lymphoma? Are you looking for options to treat your cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called iC9-CAR19 with Rimiducid.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

Study of CAR-T cells in relapsed/refractory Hodgkin's Lymphoma and Cutaneous T-Cell Lymphoma

Do you have Hodgkin's Lymphoma or Cutaneous T-Cell Lymphoma? Has your lymphoma come back, or has it not gotten better after your last treatment? If so, you might be able to take part in a study that will modify your own immune cells to see if it may treat your lymphoma.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

CD30 CAR-T cells for Hodgkin's/Non-Hodgkin's Lymphom

Do you have lymphoma that has come back, or did not get better with the last treatment you were given? If so, you might able to participate in a study to see if the study team can make modified T cells that are able to fight and kill the lymphoma cells.

Age & Gender
  • 3 years ~ 17 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Visit Location
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research